The latest specific price of ruxolitinib tablets/ruxolitinib

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is an oral selective Janus kinase (JAK1/2) inhibitor. It has been widely used in the treatment of myeloproliferative diseases in recent years, especially in the fields of polycythemia vera, myelofibrosis and steroid-refractory graft-versus-host disease (GVHD). It has shown unique advantages. Its mechanism of action is mainly through inhibiting the abnormally activated JAK-STAT signaling pathway, thereby regulating cytokine levels, improving spleen enlargement and hematological abnormalities, and alleviating related symptoms. Due to its strong specificity, ruxolitinib has become an important drug recommended by many international guidelines.

In China, the original drug ruxolitinib is marketed as "ruxolitinib phosphate tablets" and has been included in Class B medical insurance, which greatly reduces the financial burden on patients. Common drug specifications include 20mg, 14 tablets, and 5mg, 60 tablets. The market price per box is about RMB 3,000. After medical insurance reimbursement, the pressure on patients to pay out of pocket is significantly reduced. Due to differences in medical insurance policies and channels in different regions, prices may fluctuate slightly.

In overseas markets, ruxolitinib also has a high usage rate. Taking the Turkish version of the original drug as an example, the price of 60 tablets of 5 mg is usually around 4,000 yuan. The price fluctuates to a certain extent due to the local market environment and exchange rate fluctuations. In addition, as patent protection gradually expires, generic versions of drugs have begun to be marketed in many countries. Take the generic drug produced by a Bangladeshi pharmaceutical factory as an example. The specification is 5mg and 50 tablets. Each box is priced at more than 1,000 yuan, which has a clear price advantage compared to the original drug. This type of generic drugs is consistent with the original drugs in terms of drug ingredients and basic efficacy, providing more accessible options for patients with heavy financial burdens.

In terms of purchasing channels, domestic patients mainly obtain original drugs through hospital pharmacies and pharmacies, and can also enjoy medical insurance reimbursement policies. Original and generic versions can also be found on overseas or cross-border drug purchase platforms. Patients should pay attention to the legal compliance of drug sources when choosing to ensure safety and efficacy.

Reference materials:https://www.jakavi.com/